Abstract
In the EU, romiplostim was recently indicated for the treatment of immune thrombocytopenia in patients with disease duration ≤ 12 months (early ITP). In clinical practice, most patients receive romiplostim for chronic ITP. This study assessed the cost-effectiveness of romiplostim in the treatment of early versus chronic ITP in the Czech Republic.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
